99 results about "Contraceptive drugs" patented technology

The present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptives (“POC”), such as Drospirenone.

The invention discloses a method of acquiring high-purity 17 alpha-acetoxy-11 beta-(4-N, N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, comprising the following steps: a) putting the acquired crude 17 alpha-acetoxy-11 beta-(4-N, N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione in a proper solvent system to generate a pure 17 alpha-acetoxy-11 beta-(4-N, N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione solid; b) separating the 17 alpha-acetoxy-11 beta-(4-N, N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione solid; and c) carrying out recrystallization on the acquired solid. The compound used as a new oral emergency contraception can be taken in 120 h after unprotected sexual intercourse of women without a reduction of emergency contraception effect with the delay of the time of using drugs, and has good safety and survivability simultaneously.

A multiphasic method of contraception comprising the steps of sequentially administering to a female of child bearing age a Phase I composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 15 mcg of ethinyl estradiol for about 7 to about 14 days; a Phase II composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 10 to about 25 mcg of ethinyl estradiol for about 14 to about 22 days; a Phase III composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 15 to about 35 mcg of ethinyl estradiol for about 20 to about 31 days; and an optional Phase IV composition containing (i) an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol, or (ii) a placebo or a non-steroidal component, or (iii) a combination of (i) and (ii), for about 2 to about 8 days. The ethinyl estradiol equivalent amount of estrogen in each of the successive Phases II and III is at least 5 mcg greater than the ethinyl estradiol equivalent amount of estrogen in the immediately-preceding phase.

The provided human epididymis specific express protein ESC42 with coded sequence can be prepared by chemical method or genetic engineering technique, and can be used to prepare antibacterial drug or new contraceptive.

The invention provides a percutaneous contraceptive drugs delivery system and method, wherein the delivery system (TCDS) comprises a back lining layer, a viscous polymeric medicine storage layer adhered on the back lining layer, a strippable protective layer adhered on the viscous polymeric medicine storage layer, the viscous polymeric medicine storage layer comprises skin permeable accelerant composition, humectant, viscous polymer, active dosage of one or more steroid hormones, wherein the skin permeable accelerant composition is a mixture of dimethyl sulphoxide, 2-hydroxypropanoic aliphatic alcohol ester, diethylene glycol alkyl ether and oleinic acid by the initial weight ratio of 2 : 1 : 1 : 0.8 to 5 : 1 : 1 : 0.8. The invention can substantially improve steroid hormone transdermal speed and increase TCDS effectiveness and convenience.

The invention discloses a temperature sensitive injectable drug-loading controlled release system, which comprises a star-shaped poly-lactic-co-glycolic acid-methoxy polyethylene glycol segmented copolymer and a simulated body fluid, and the content of the copolymer accounts for 15-40 weight by percent. The drug-loading controlled release system exists in a state of liquid which can freely flow in or below room temperature, is rapidly changed into oyster white physical crosslinking hydrogel which cannot flow at a human body temperature, and expresses a reversible sol- gel conversion behavior; the drug-loading controlled release system can uniformly disperse a loaded drug, and exists in a state of liquid which can freely flow in or below room temperature and gel which cannot freely flow at the body temperature; as a vagina drug-loading controlled release system, the temperature sensitive injectable drug-loading controlled release system has the characteristics that contraceptive compound estrogen, progestogen and an anti-inflammation drug are loaded into a copolymer hydrogel carrier by adopting a solution blending method, and the prepared drug-loading system serves as a birth control spraying agent; the drug-loading system is sprayed into vagina after women menses, and is shaped into mesh gel and attached into a wall, and the drug is slowly and controllably released and have an effect of birth control.

The invention discloses a prescription technique for improving the stability of desogestrel. According to the prescription technique, active medicines of the prescription are dissolved in a solvent mixture of which the weight is 5-200 times the weight of the active medicine; the active medicines are desogestrel and ethinylestradiol; the solvent mixture is chloroform or other solvent mixtures; and the active medicines are completely dissolved in the solvent mixture, and then an antioxygen of which the amount is 2-10 times the amount of the active medicines is added; the antioxygen including vitamin C or vitamin E is dissolved, so that the active medicines and the antioxygen are a solution at molecular distribution state, and each active medicine molecule is surrounded and protected by a plurality of antioxygen molecules. The prescription technique disclosed by the invention improves the stability of main medicines of the oral contraceptive and has the advantage that the shelf time of the oral contraceptive consisting of desogestrel and ethinylestradiol is as long as 24 months, etc.

The present invention relates to a device or preventing transmission of body fluids between two persons during sexual relations. The device is formed of an elastic material and has a first inner side, coated with a glue contrived to fix said device to at least a part of the man's sexual organ, and a second part contrived to burst upon ejaculation.

The invention provides an oral preparation capable of dosing fertility-controlling drugs by positioning at small intestine and a production method thereof. The fertility-controlling drug positioning at small intestine is prepared by wrapping one or plural layers of coatings on solid oral fertility-controlling drug preparation or directly using slow-release capsules so as to enable the preparation not to dissolve in gastric acid but dissolve at the small intestine part where the acidity is nearly neutral, thus causing the drugs to release and to be absorbed in the intestine, successfully avoiding the circumstances of vomiting owing to gastricsolubility of oral fertility-controlling drugs and inaccurate drug dosage whivh results in failure of fertility-controlling.